Establishment Labs (ESTA) Stock Price, News & Analysis

Company Overview

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a medical technology company focused on women’s health and breast aesthetics. The company develops, manufactures and markets medical devices intended for breast augmentation, reconstruction and related procedures.

Its principal product portfolio includes Motiva breast implants, a line of silicone-gel implants designed for aesthetic and reconstructive applications, as well as tissue expanders and other products used in breast surgery. Establishment Labs also offers Mia Femtech, a technology and procedure platform designed to support a less invasive approach to breast augmentation.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves healthcare providers and patients in international markets. Its products have been distributed globally, with the company historically maintaining a presence across Europe, Latin America, Asia and other regions. The company was founded by Juan José Chacón-Quesada, who serves as its chief executive officer.

Key Stats

• Today's Range: $55.05 to $59.01
• 50-Day Range: $58.45 to $91.25
• 52-Week Range: $44.22 to $97.59
• Volume: 33,467 shs
• Average Volume: 512,816 shs
• Market Capitalization: $1.75 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.25
• Consensus Rating: Moderate Buy

Establishment Labs Stock Analysis - MarketRank™

Establishment Labs scored higher than 57% of companies evaluated by MarketBeat, and ranked 294th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Establishment Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Establishment Labs has a consensus price target of $100.25, representing about 71.5% upside from its current price of $58.45.

Amount of Analyst Coverage

Establishment Labs has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Establishment Labs are expected to grow in the coming year, from ($1.15) to $0.01 per share.

Price to Book Value per Share Ratio

Establishment Labs has a P/B Ratio of 72.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.85% of the float of Establishment Labs has been sold short.

Short Interest Ratio / Days to Cover

Establishment Labs has a short interest ratio ("days to cover") of 12.08, which indicates bearish sentiment.

Change versus previous month

Short interest in Establishment Labs has recently decreased by 9.20%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Establishment Labs does not currently pay a dividend.

Dividend Growth

Establishment Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.79

News Sentiment

Establishment Labs has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Establishment Labs this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for ESTA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Establishment Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.99% of the stock of Establishment Labs is held by insiders.

Percentage Held by Institutions

72.91% of the stock of Establishment Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ESTA
• CIK: 1688757
• Web: www.establishmentlabs.com
• Phone: (062) 434-2400
• Fax: N/A
• Employees: 1,004
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Establishment Labs: $100.25
• High Price Target: $117.00
• Low Price Target: $90.00
• Potential Upside/Downside: +71.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.06 million
• Net Margins: -15.82%
• Pretax Margin: -19.31%
• Return on Equity: -196.69%
• Return on Assets: -10.73%

Debt

• Debt-to-Equity Ratio: 12.11
• Current Ratio: 3.84
• Quick Ratio: 2.52

Sales & Book Value

• Annual Sales: $211.08 million
• Price / Sales: 8.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.81 per share
• Price / Book: 72.39

Miscellaneous

• Outstanding Shares: 29,800,000
• Free Float: 26,825,000
• Market Cap: $1.75 billion
• Optionable: Optionable
• Beta: 1.06